期刊
EXPERT OPINION ON THERAPEUTIC TARGETS
卷 16, 期 2, 页码 209-223出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/14728222.2012.658370
关键词
fatty acids; IL-6; NF-kappa B; PPAR beta/delta; STAT-3
资金
- Ministerio de Ciencia e Innovacion of Spain [SAF2009-06939]
Introduction: The nuclear receptors Peroxisome Proliferator-Activated Receptors (PPAR)alpha and PPAR gamma are therapeutic targets for hypertriglyceridemia and insulin resistance, respectively. Evidence is now emerging that the PPAR beta/delta isotype is a potential pharmacological target for the treatment of insulin resistance and type 2 diabetes mellitus. Areas covered: In this review, the capacity of PPAR beta/delta to prevent the development of insulin resistance and type 2 diabetes mellitus is discussed. Special emphasis is placed on preclinical studies and the molecular mechanisms responsible for its actions in the main cell types involved in these pathologies: adipocytes, beta-cells, skeletal muscle cells and hepatocytes. Expert opinion: While several concerns remain for the development of PPAR beta/delta agonists, these drugs have demonstrated their efficacy in the treatment of insulin resistance and type 2 diabetes mellitus in preclinical studies, as well as in a few short clinical studies in humans. Although this data is promising, additional studies must be performed to confirm the efficacy and safety of these drugs in the treatment of type 2 diabetes mellitus.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据